Severe erythema exudative multiforme developing from advanced melanoma treated with dabrafenib and trametinib followed by nivolumab
Author:
Affiliation:
1. Department of Dermatology; Tohoku University Graduate School of Medicine; Sendai Japan
Publisher
Wiley
Subject
Dermatology,General Medicine
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/1346-8138.14085/fullpdf
Reference5 articles.
1. Toxic epidermal necrolysis induced by vemurafenib after nivolumab failure;Arenbergerova;J Eur Acad Dermatol Venereol,2017
2. Unexpected recalcitrant course of drug-induced erythema multiforme-like eruption and interstitial pneumonia sequentially occurring after nivolumab therapy;Nomura;J Dermatol,2017
3. Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma;Sanlorenzo;J Am Acad Dermatol,2014
4. Keratoacanthoma, palmoplantar keratoderma developing from an advanced melanoma patient treated with vemurafenib regressed by the blockade of MEK signaling;Furudate;J Dermatol,2017
5. Crucial Role of Viral Reactivation in the Development of Severe Drug Eruptions: a Comprehensive Review;Shiohara;Clin Rev Allergy Immunol,2015
Cited by 8 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Severe lichenoid eruption due to concomitant medications following nivolumab administration;JEADV Clinical Practice;2023-06
2. Immunotherapy for Melanoma: The Significance of Immune Checkpoint Inhibitors for the Treatment of Advanced Melanoma;International Journal of Molecular Sciences;2022-12-11
3. Treatment of Advanced Melanoma: Past, Present and Future;Life;2020-09-16
4. Drug-Induced Uveitis: Part 1;Advances in Ophthalmology and Optometry;2020-08
5. HLA-DRB1*04:05 in two cases of Vogt-Koyanagi-Harada disease-like uveitis developing from an advanced melanoma patient treated by sequential administration of nivolumab and dabrafenib/trametinib therapy;The Journal of Dermatology;2018-02-27
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3